SEC Filing · S-8
Yarrow Bioscience, Inc.
YARWNASDAQEQUITYCurrent
SEC Filing
Company context
Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, a potentially first-in-class anti-thyroid stimulating hormone receptor (“TSHR”) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both GD and TED. For more information, visit www.yarrowbioscience.com.
Current securities
Historical securities (1)
Recent company filings
- SCHEDULE 13G/A - filed by PERCEPTIVE ADVISORS LLC regarding Yarrow Bioscience, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by Janus Henderson Group Ltd. regarding Yarrow Bioscience, Inc.Nov 16, 2026
- SCHEDULE 13G - filed by AMERIPRISE FINANCIAL INC regarding Yarrow Bioscience, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by Nantahala Capital Management, LLC regarding Yarrow Bioscience, Inc.Nov 13, 2026
- 10-Q filingNov 13, 2026
As-filed source
As filedOpen full document ↗